Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986548 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A Monotherapy Dose Escalation: BMS-986548 | EXPERIMENTAL | - |
| Part 1B Combination Dose Escalation: BMS-986548 + Cetuximab | EXPERIMENTAL | - |
| Part 2A Monotherapy Dose Expansion: BMS-986548 | EXPERIMENTAL | - |
| Part 2B Combination Dose Expansion: BMS-986548 + Cetuximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986548 | DRUG | Specified dose on specified days |
| Cetuximab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification). * Participants must have an Eastern Coo...
BMS-986548 is an investigational small molecule being studied for the treatment of advanced solid malignancies. It is being evaluated both as a monotherapy and in combination with anti-cancer agents in adults with these advanced cancers. It is not yet an approved treatment.
BMS-986548 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is the sponsor of the clinical program evaluating the compound in advanced solid malignancies.
BMS-986548 is in Phase 1/2 clinical development. It is investigational and has not been approved by the FDA. The program consists of a single Phase 1/Phase 2 study that is currently active but not yet recruiting participants.
BMS-986548 is being studied in trial NCT07939815, titled a study of BMS-986548 as monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies. The Phase 1/Phase 2 trial is not yet recruiting and plans to enroll 171 participants across the United States and Canada.
The NCT07939815 trial enrolls adults aged 18 years and older of all sexes with advanced solid malignancies. It does not include healthy volunteers, and the study is biomarker selected, meaning participants are chosen based on a defined biomarker. The trial is controlled and is not randomized or double blinded.